OncoMatch/Clinical Trials/NCT06796907
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Is NCT06796907 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Mo-Rez and Dostarlimab for tumours, gynecological.
Treatment: Mo-Rez · Dostarlimab · Bevacizumab — Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Endometrial Cancer
Ovarian Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
confirmed mismatch repair proficient (MMRp) or microsatellites stable (MSS) tumor status by local test
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — endometrial cancer
Participants who have progressed on or are intolerant to at least 1 line of standard prior systemic therapy (including neoadjuvant or adjuvant as prior line)
Must have received: chemotherapy — ovarian cancer
Participants who have progressed on or are intolerant to at least 1 line of standard prior lines of chemotherapy and are not candidates for second cytoreductive surgery
Cannot have received: allogenic or autologous bone marrow transplant
any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant
Cannot have received: topoisomerase-1 inhibitor
prior therapy with topoisomerase-1 inhibitors or ADC with topoisomerase-1 inhibitor warhead
Cannot have received: antibody-drug conjugate with topoisomerase-1 inhibitor warhead
prior therapy with topoisomerase-1 inhibitors or ADC with topoisomerase-1 inhibitor warhead
Cannot have received: B7H4 targeted therapy
prior therapy with ... B7H4 targeted therapy
Lab requirements
Blood counts
Participants with normal organ and bone marrow function required
Kidney function
active renal condition (e.g., infection, requirement for dialysis, or any other active significant renal condition or dehydrated condition that could affect the participant's safety) is exclusionary; renal obstruction successfully managed by stenting is permitted
Liver function
ALT value >2.5x ULN (or >5x ULN with liver metastases/tumor infiltration) and total bilirubin >1.5x ULN are exclusionary
Cardiac function
history in prior year of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, NYHA Class III or IV congestive heart failure or clinically significant arrhythmia not controlled by standard of care therapy; QTcF >450 msec or >480 msec for bundle branch block; history of CHF or baseline LVEF <50% or institutional lower limits of normal
Participants with normal organ and bone marrow function. Exclusion: ALT value >2.5x ULN (or >5x ULN with liver metastases/tumor infiltration), total bilirubin >1.5x ULN, cardiac exclusion criteria as listed.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · La Jolla, California
- GSK Investigational Site · Rochester, New York
- GSK Investigational Site · Durham, North Carolina
- GSK Investigational Site · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06796907 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogenic or autologous bone marrow transplant, topoisomerase-1 inhibitor, antibody-drug conjugate with topoisomerase-1 inhibitor warhead disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 wild-type is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages